|
FBXO22 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.559400E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.404480E-04 |
| Normal-vs-Stage2 |
3.859900E-02 |
| Normal-vs-Stage3 |
2.670400E-02 |
| Normal-vs-Stage4 |
3.594400E-01 |
| Stage1-vs-Stage2 |
6.239800E-01 |
| Stage1-vs-Stage3 |
2.377600E-01 |
| Stage1-vs-Stage4 |
1.504150E-02 |
| Stage2-vs-Stage3 |
7.328800E-01 |
| Stage2-vs-Stage4 |
2.009200E-01 |
| Stage3-vs-Stage4 |
2.419800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.604800E-04 |
| Normal-vs-AfricanAmerican |
3.352300E-02 |
| Normal-vs-Asian |
3.112300E-02 |
| Caucasian-vs-AfricanAmerican |
9.905200E-01 |
| Caucasian-vs-Asian |
7.616400E-01 |
| AfricanAmerican-vs-Asian |
8.391200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.174400E-02 |
| Normal-vs-Female |
3.161100E-04 |
| Male-vs-Female |
2.695600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.192100E-04 |
| Normal-vs-Age(41-60Yrs) |
5.158600E-03 |
| Normal-vs-Age(61-80Yrs) |
5.995600E-02 |
| Normal-vs-Age(81-100Yrs) |
8.265600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.493750E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.730000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.083000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.011200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.853000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.245400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.966600E-01 |
| Classical-VS-Follicular |
3.422100E-02 |
| Classical-VS-Other |
7.195800E-01 |
| Classical-VS-Normal |
4.02830000000298E-05 |
| Tall-VS-Follicular |
4.565000E-01 |
| Tall-VS-Other |
9.385000E-01 |
| Tall-VS-Normal |
4.774000E-02 |
| Follicular-VS-Other |
6.990200E-01 |
| Follicular-VS-Normal |
2.148400E-01 |
| Other-VS-Normal |
2.050400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.123700E-03 |
| Normal-vs-N1 |
1.936210E-01 |
| N0-vs-N1 |
6.137600E-01 |
|
|
